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Abstract
Aim Lung metastases from colorectal cancer are
resected in selected patients in the belief that this con-
fers a significant survival advantage. It is generally
assumed that the 5-year survival of these patients would
be near zero without metastasectomy. We tested the
clinical effectiveness of this practice in Pulmonary
Metastasectomy in Colorectal Cancer (PulMiCC), a ran-
domized, controlled noninferiority trial.
Method Multidisciplinary teams in 14 hospitals recruited
patients with resectable lung metastases into a two-arm
trial. Randomization was remote and stratified according
to site, with minimization for age, sex, primary cancer
stage, interval since primary resection, prior liver involve-
ment, number of metastases and carcinoembryonic anti-
gen level. The trial management group was blind to
patient allocation until after intention-to-treat analysis.
Results From 2010 to 2016, 93 participants were ran-
domized. These patients were 35–86 years of age and
had between one and six lung metastases at a median of
2.7 years after colorectal cancer resection; 29% had
prior liver metastasectomy. The patient groups were
well matched and the characteristics of these groups
were similar to those of observational studies. The med-
ian survival after metastasectomy was 3.5 (95% CI: 3.1–
6.6) years compared with 3.8 (95% CI: 3.1–4.6) years
for controls. The estimated unadjusted hazard ratio for
death within 5 years, comparing the metastasectomy
group with the control group, was 0.93 (95% CI: 0.56–
1.56). Use of chemotherapy or local ablation was infre-
quent and similar in each group.
Conclusion Patients in the control group (who did not
undergo lung metastasectomy) have better survival than
is assumed. Survival in the metastasectomy group is
comparable with the many single-arm follow-up studies.
The groups were well matched with features similar to
those reported in case series.
Keywords Colorectal cancer, lung metastasectomy,
randomized controlled trial
Background
The lung is a common site of metastases and, since the
earliest days of chest radiography, has been the site
where metastases are most easily detected. Their
removal has been documented in case reports and in
small follow-up studies since the early days of thoracic
surgery [1]. However, the claimed benefit of lung
metastasectomy was challenged 40 years ago by Torkel
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Aberg. Introducing a small comparative study in 1980,
he wrote, ‘It has been assumed, implied, or claimed that
the 5-year survival without operation is nil. Control
material is, however, lacking’ [2]. His paper has rarely
been cited [3].
Publication of the International Registry of Lung
Metastases in 1997 was a landmark in the adoption of
pulmonary metastasectomy [4]. The registry featured
5206 patients who had undergone a lung metastasec-
tomy but included no information about patients who
did not have a metastasectomy. The inherent assump-
tion was that survival would have been negligible with-
out resection of the metastases. This point is illustrated
in a statement from a National Institute for Health and
Care Excellence (NICE) guideline published in 2004:
‘Surgery for patients with metastases confined to the . . .
lung . . . can improve five-year survival from close to
zero to over 30%’ [5]. This guideline is no longer acces-
sible but was cited verbatim in an Analysis article in the
BMJ in 2007 [6], pointing out the absence of evidence.
The assumed low survival rate was re-emphasized in an
authoritative Rapid Response stating: ‘We have known
the natural history of under-treated metastatic colorectal
cancer for over a decade’ [7].
The numbers of metastasectomy operations for col-
orectal cancer (CRC) grew between 2000 and 2011
without any controlled trials [8,9], during a time when
many randomized controlled trials (RCTs) of systemic
therapies were conducted [10]. A literature search
undertaken for a systematic review published in 2010
found 101 papers published on CRC lung metastasec-
tomy [11]. None provided control data. This was the
reason for running the Pulmonary Metastasectomy in
Colorectal Cancer (PulMiCC) trial. Recruitment was
poor, probably because of the entrenched belief that
lung metastasectomy was life-saving. The trial was
stopped early, with analysable data available for 65 ran-
domized patients [12]. Data on a further 28 random-
ized patients became available after the trial was
published. An updated survival analysis is presented
here, providing information on all 93 randomized
patients at a date 18 months later than in the first pub-
lication.
Detection and treatment of metastases is central to
the Impact Initiative (Improving Management of
Patients with Advanced Colorectal Tumours) of the
Association of Coloproctology of Great Britain and Ire-
land (ACPGBI) [13]. High among the research priori-
ties considered in a modified Delphi approach is the
question: ‘What is the optimal timing of resection of
liver and/or lung metastases from colorectal cancer –
before, during or after primary surgery?’ [14]. From the
outset we make it clear that our paper concerns only
lung metastases and the effect of metastasectomy on
survival. Lung metastases considered for elective resec-
tion are asymptomatic so it is important to know how
much survival benefit, if any, is actually gained because
this is the motive for their removal.
Method
A full account of the methods has already been pub-
lished [12]. Below is an abbreviated version that
includes the supplementary methods used for follow-up
of the additional patients and the new analysis.
Study design
PulMiCC is a randomized Phase III, parallel-arm, mul-
ticentre noninferiority trial conducted in hospitals treat-
ing advanced CRC. The principal investigators (PIs)
were oncologists or surgeons working in multidisci-
plinary teams (MDTs). The randomized trial ran at 13
sites in England and one in Serbia.
The trial was coordinated initially by the Clinical Tri-
als and Evaluation Unit, Royal Brompton and Harefield
NHS Foundation Trust, London, and later by the Sur-
gical and Interventional Trials Unit (SITU), University
College London.
Ethical approval and consent to participate
The National Research Ethics Service (NRES) granted
ethical approval (no. 10/H0720/5) and recruitment
began at each site after approval of local Ethics Com-
mittees. Written informed consent was obtained at
enrolment and again at randomization (Stages 1 and 2,
respectively). The trial protocol is available online
(https://www.ucl.ac.uk/clinical-operational-research-
unit/sites/clinical-operational-research-unit/files/pul
micc_protocol_december_2015.pdf).
Patient participants
Adults who had resection of a CRC with a prospect of
cure, but were found to have lung metastases, were
recruited. There had to be no other sites of CRC other
than treated liver metastases. The MDTs were required
to have proven that these were CRC metastases or to
have 90% clinical confidence that this was the diagnosis.
Potential patients were invited to participate and gave
initial consent to be monitored. If the MDT was uncer-
tain as to whether a patient might or might not benefit
from pulmonary metastasectomy, the patient was invited
to enter the second phase of the study. If they con-
sented, they were randomized either to metastasectomy
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or observation. The 419 who did not consent to be
randomized continued to be monitored and that cohort
will be the subject of a separate analysis.
Randomization and masking
The randomization was to control or metastasectomy
arms, with both arms similarly monitored. Patients were
allocated equally, with stratification according to site.
The sequence was generated at www.sealedenvelope.co.
uk with minimization for age, sex, T(umour) stage, N
(odal) stage, previous hepatic resection, interval since
surgery for CRC, number of metastases and carcino-
genic embryonic antigen (CEA) assay results, while
retaining a random element. Minimization is largely a
deterministic procedure that guarantees balance in strat-
ifying factors and limits the potential for unexpected
confounding [15–17]. The request and the assignment
were communicated remotely, ensuring concealment
from the trial centre and the sites. Masking at sites was
deemed impossible but the assignment was not revealed
to the trial management group until the analysis was
completed.
Metastasectomy was performed by surgical resection,
using either videothoracoscopy or open thoracotomy at
the discretion of the surgeon.
Control patients were not treated initially with any
local intervention, such as radiotherapy or image-guided
thermal ablation (IGTA).
Outcomes
The primary outcome in the PulMICC trial was overall
survival over the 5 years following from the date of ran-
domization. Also reported in this paper is information
on subsequent survival up to the date of the analysis.
Data collection
The case report forms (CRFs) for patients in English
centres were to be returned at 3, 6, 9, 12, 18, 24, 36,
48 and 60 months. Any treatment since the last report
was recorded. Crossover effects were reflected in the as-
treated secondary analysis. For Serbian patients, data
return had fallen into abeyance because of insurmount-
able difficulties at the time, and analysis was performed
on the 65 available patients and published in 2019
[12]. Data were extracted from the standard CRFs
returned at intervals as specified. Late or missing CRFs
and missing fields were pursued by the Trials unit.
Thereafter the PIs were contacted directly by the chief
investigator (CI). Throughout this process the CI had
no access to the assigned arms.
The CI was informed by the local PI on 24 Novem-
ber 2019 that the difficulties had been overcome. After
exploration of the feasibility and likely completeness of
the data, and with the agreement of the Chair of the
Independent Data Monitoring Committee, patient-
specific CRFs requesting date of death or date last
known to be alive, plus dates and nature of additional
treatments for the Serbian patients, were sent out on 24
December 2019. These CRFs were returned on 21 Jan-
uary 2020 with a high level of compliance and com-
pleteness. Uncertainties or ambiguities concerning any
of the 93 patients during this re-analysis were resolved
by exchanges of emails between the CI and the site PIs.
Data entry for this second analysis was closed on 29
February 2020. Other information such as that from
protocol-determined lung function tests, were not avail-
able or retrievable and so was not requested.
Statistical analysis
Sample size
A 10% difference in overall mortality at 3 years was
taken to be the inferiority margin for the design of the
PulMiCC noninferiority trial. A sample size of 1350
registered patients was estimated to provide 1:1 ran-
domization of 300 patients.
Comparative analysis
For the primary outcome of survival, date of death and
date last known alive were updated with a closing date
of 29 February 2020. For comparative analysis, survival
times were examined, and Kaplan–Meier estimates of
survival curves were produced. Nonparametric CIs for
survival times and quantiles were calculated using the R
package ‘bpcp’ [18]. A Cox relative risk regression
model [19], with an assumption of proportional haz-
ards, was used to compare treatment arms in the inten-
tion-to-treat primary analysis in which a binary
explanatory variable indicated treatment group. This
provided estimated hazard ratios and confidence inter-
vals. The assumption of proportional hazards was exam-
ined by testing for a linear trend of the treatment effect
in time. The minimization variables were used for
adjustment. For the as-treated analysis, comparison was
based on a time-dependent binary explanatory variable,
which was zero until the time at which a metastasec-
tomy occurred, when it took a value of 1 [12]. Cross-
overs are thus accounted for in this analysis.
Results
The first randomization was 2 December 2010 and the
last was 24 November 2016. The randomized trial
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closed in December 2016 because of poor recruitment.
There were 512 patients in Stage 1, of whom 93 were
randomized. The PIs, clinical sites and numbers ran-
domized at each site are listed in Table 1.
The dataset was closed on 29 February 2020, adding
18 months of follow-up for the UK patients in the previ-
ous report [12] as well as available information on sur-
vival for the Serbian patients. The median follow-up for
all patients was 3.46 years compared with 3.16 years in
the previous report. The mean follow-up for patients alive
at the last follow-up was 4.51 years compared with 3.85
in the previous report. For all but two patients, follow-up
was longer than 3 years, and 81 had been followed up for
longer than 5 years or had died before this time. Of the
93 patients randomized, 47 were assigned to the control
group and 46 to metastasectomy. No patient had metas-
tasectomy or stereotactic body radiotherapy (SBRT) to
the index metastasectomy site in the first year. The clini-
cal teams were subsequently allowed to treat as they
judged clinically appropriate, and three patients in the
control group had metastasectomy at 13, 19 and
27 months after randomization. Three patients assigned
to metastasectomy did not have it: two preferred not to
have an operation; and one was found to have progress-
ing brain involvement. One patient in each arm turned
out not, in fact, to have metastases. In one control group
patient with presumed metastases, the opacities had
resolved on a CT scan 5 months later. The patient
remains alive after 9 years. A patient assigned to metasta-
sectomy had two nodules removed, which were found to
be intrapulmonary lymph nodes, and this patient remains
alive 7.5 years later. Both patients remain in their
assigned group for intention-to-treat analyses.
There were no treatment-related deaths or major
adverse events. It should be noted that in the context
of thoracic surgery these are among the least hazardous
lung operations. Because of the highly selective nature
of the practice, unlike with lung cancer surgery, higher-
risk operations can be avoided.
Table 2 shows the balance in minimization variables
between the two treatment groups. Table 3 shows the
distributions of age, gender, CRC resection interval and
number of metastases for the two groups. Figure 1
gives a profile of the patients in the PulMICC trial. Fig-
ure 2 is a Sankey chart illustrating the flow of patients.
[http://sankeymatic.com/faq/].
Additional treatments
There were no significant differences in the intensity of
other treatments which might have altered the balance
between the groups.
The intention of the CRF question was to capture
treatment of lung metastases but in one instance in each
Table 1 Principal investigator, sites and numbers of randomized patients.
Principal investigator Clinical sites Randomizations
Misel Milosevic Thoracic Surgery Clinic, Institute for Lung Diseases of Vojvodina, Sremska Kamenica,
Serbia
28
John Edwards Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK 18
David Tsang Basildon and Thurrock University Hospitals NHS Foundation Trust, Basildon, UK 8
Joel Dunning The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust,
Middlesbrough, UK
7
Michael Shackcloth Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, UK 7
Tim Batchelor Bristol Royal Infirmary, University Hospitals Bristol NHS Foundation Trust, Bristol, UK 5
Aman Coonar Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK 5
Jurjees Hasan The Christie NHS Foundation Trust, Manchester, UK 4
Brian Davidson Royal Free London NHS Foundation Trust, London, UK 3
Adrian Marchbank Derriford Hospital, University Hospitals Plymouth NHS Trust, Plymouth, UK 2
Simon Grumett New Cross Hospital, The Royal Wolverhampton NHS Trust, Wolverhampton, UK 2
Eric Lim Royal Brompton Hospital, Royal Brompton & Harefield NHS Foundation Trust,
London, UK
2
Apostolos Nakas Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK 1
Stelios Vakis Queen’s Hospital, University Hospitals of Derby and Burton NHS Foundation Trust,
Burton upon Trent, UK
1
Total randomized 93
The total randomized (n=93) represents 18% of the total of 512 patients recruited to Pulmonary Metastasectomy in Colorectal
Cancer (PulMiCC).
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group the reported radiotherapy was to treat metastases
elsewhere (brain and bone). However, there is no evi-
dence that patients were treated with radiotherapy to
the index lesion if they were assigned to the non-metas-
tasectomy group. The only IGTA used was radio fre-
quency ablation (RFA): In addition to the treatment in
the table, one patient in each group and repeated RFA
to a total of 3 treatments in each case.
Additonal treatments are in Table 4.
Survival
Updated primary trial outcome analyses
Restricting attention to 5 years of follow-up, as speci-
fied for the primary analysis of the trial, 58 deaths (31
in the control group and 27 in the metastasectomy
group) were recorded at the close of the analysis. Fig-
ure 3 presents a Kaplan–Meier estimate of the survival
curves for the control and metastasectomy arms.
Comparison of survival rates in the metastasectomy
arm with those in the control arm, adjusting for and
therefore comparing patients with comparable mini-
mization variables, gave an estimated hazard ratio of
0.87 with a 95% CI of 0.51–1.48. There was no evi-
dence for a nonproportional hazard (P = 0.47). The
unadjusted estimated hazard ratio was 0.93 (95% CI:
0.56–1.56). For the ‘as-treated’ analyses, the compara-
ble adjusted and unadjusted estimated hazard ratios
were 0.73 (95% CI: 0.42–1.28) and 0.81 (95% CI:
0.48–1.37).
Complete survival data
Over the entire follow-up period, 63 deaths were
recorded: 33 in the control arm and 30 in the metasta-
sectomy arm. Table 5 presents the observed minimum
and maximum survival times in both arms and the esti-
mated nonparametric 25%, 50% (median) and 75%
quantiles of the time-to-death distributions along with
associated 95% CIs. The tabulated values are very simi-
lar in both arms, with differences only seen in the 75%
quantiles, which are estimated from very limited data.
The median survival after metastasectomy was 3.5 (95%
CI: 3.1–6.6) years compared with 3.8 (95% CI: 3.1–
4.6) years for controls.
Overall estimated survival at 4 years was 47.1% (95%
CI: 31.9%–62.6%) for control patients and 44.4% (95%
CI: 28.8%–60.6%) for metastasectomy patients, with the
respective 5-year survival values being 29.6% (95% CI:
15.3%–45.7%) and 36.4% (95% CI: 21.3%–53.0%). The
estimated 4-year survival percentages are closer than
reported previously, and the 5-year percentages are
comparable [12]. There is a numerical difference in esti-
mated 5-year rates because there were seven (of 20)
deaths in the control arm in year 5 and three (of 17) in
the metastasectomy arm. Note, however, that the
deaths in the metastasectomy arm occurred earlier in
year 5 than those in the control arm. Subsequently,
there were three and two deaths in the two arms,
respectively.
Respiratory function and Patient Reported Outcome
Measures were reported in 2019 for 65 randomised
patients [12]. There are no further data to report here.
Discussion
The main limitations of the PulMiCC trial are small
numbers and early closure [12]. This update increases
the numbers by 43% and adds 18 months of follow-up
information for all patients. The 5-year survival in the
Table 2 Data obtained at baseline in all patients and used in
the minimization step in randomizing patients to the two trial
arms.
Characteristic
Group 1
(N = 47)
Group 2
(N = 46)
Control Metastasectomy
Gender
Male 28 31
Female 19 15
Age (years)
61+ 33 32
60 or under 14 14
Lung metastases
1 16 18
2–4 26 24
5+ 5 4
CEA (ng/ml)
<5 36 37
5–10 6 6
10+ 5 3
Prior liver resection
Yes 13 14
No 34 32
Years since 1o CRC resection
<1 7 7
1–3 28 26
3+ 12 13
CRC Stage
T stage
1 2 2
2 8 7
3+ 37 37
N Stage
0 25 24
1+ 22 22
Values represent the number of patients.
CEA, carcinoembryonic antigen; CRC, colorectal cancer.
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well-matched control group is 29.6% (95% CI: 15.3%-
45.7%). This undermines the ‘close to zero’ assumption
for the survival of patients with CRC lung metastases
without lung metastasectomy.
Power calculations are based on the most reliable
data available when planning the study. The power cal-
culation for PulMiCC was not based on a ‘close to
zero’ assumption because a modelling study based on
UK cancer registry data, carried out in 2008, had indi-
cated that 5-year survival in the control group was likely
to be much higher than assumed [20]. After careful sta-
tistical consideration, we based the power calculation on
finding a difference, of less than 10%, in overall mortal-
ity at 3 years, assuming 3-year survival in the metasta-
sectomy group of 30%, substantially less than actually
observed. Small differences require large numbers and
so the power calculation required 300 patients to have
sufficient expected information to examine a 10% non-
inferiority margin for continued active monitoring com-
pared with metastasectomy.
There are occasional patients reported or remem-
bered who survive a long time and in whom lung
metastases eventually appear to have been the only can-
cer remaining. However, in this controlled trial most
patients went on to die of disseminated cancer at a simi-
lar rate, regardless of whether they did or did not have
lung metastasectomy. This attrition is also seen in
observational reports. The results of PulMiCC are
inconclusive for the main intended outcome, but the
finding of a much higher-than-expected survival of the
control patients, compared with what is assumed in
nonrandomized (observational) studies, is important.
We know of two other randomized trials in which
the effectiveness of local treatment of metastases was
tested, both of which also found higher survival in the
control group than expected by the trialists. The
CLOCC trial tested RFA for liver metastases and
SABR-COMET tested stereotactic radiotherapy for any
primary site and any secondary site (except brain). The
5-year survival in the treated arms was 40%–45%, as
reported for lung metastasectomy, but 5-year survival
was 30% and 25% in the control groups, similar to the
30% reported here for PulMiCC control patients. Sur-
vival without metastasectomy in CLOCC and PulMiCC
taken together, a combined total of 106 patients with
CRC metastases, was 30% (95% CI: 21%-40%) derived
using a complementary log-log scale. The authors of
CLOCC wrote that ablation of metastases ‘results in an
excellent survival, which however was also achieved in
the control arm’ [21] and the authors of SABR-
COMET commented that the ‘better-than-expected
survival in both groups suggest that oligometastatic can-
cers behave more indolently than previously appreci-
ated’ [22]. They had been misled by the ‘close to zero’
assumption. Also it should be noted that in both of
these trials (CLOCC and SABR-COMET) there were
Table 3 Distributions of all patients, stratified according to gender and arm to which they were assigned at randomization (top).
Characteristic Minimum 25% 50% 75% Maximum
Age (years)
Male
Control N = 27/27 55.4 62.4 68.5 74.2 86.5
Metastasectomy N = 31/31 35.3 58.5 66.4 72.1 82.8
Female
Control N = 20/20 48.2 54.3 61.3 74.3 83.2
Metastasectomy† N = 14/15 50.8 64.4 71.6 64.4 76.5
CRC resection interval (months)
Control‡ N = 46/47 2.0 17.2 27.4 35.0 130.5
Metastasectomy§ N = 45/46 1.0 13.8 23.1 36.8 106.5
Number of metastases
Control¶ N = 46/47 1 1 2 3 8
Metastasectomy N = 46/46 1 1 2 3 6
Values are given as minimum, maximum and quantiles. The quantile distribution of the number of metastases is as follows: for 1, 2, 3, 4 and 5
metastases the exact numbers for control patients were 16, 16, 7, 3 and 3, and for metastasectomy patients they were 16, 17, 8, 2 and 1, with one
patient in each arm having more than 5 metastases – 8 and 6, respectively.
†We know from minimization data that the age category of the missing patient was 61+ years.
‡From minimization data, the missing colorectal cancer (CRC) resection interval [i.e., the time elapsed between the primary CRC
resection and the metastasectomy operation] was 1–3 years.
§The missing CRC resection interval was <1 year.
¶From minimization data, the metastasis count was >5.
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Patients consented in stage 1 N = 512
Randomised
PulMiCC
N = 93
Group 1 N =47 Group 2 N =46
Metastasectomy
43 Treated as assigned
2 Not operated patients preference
1 Not operated CNS progression
(1 Nodules were benign)
Control
47 Treated as assigned
(3 Metastastectomy
operations 13, 19 & 27 m)
(1 Nodules disappeared)
32 Dead <5 years
11 Alive >5 years
4 Alive <5 years
47 Total
28 Dead <5 years
12 Alive >5 years
6 Alive <5 years
46 Total
Non-randomised
Cohort
N = 419
To be reported
Figure 1 Consort flow diagrams of the randomized trial. CNS, central nervous system; m, months; PulMiCC, Pulmonary Metasta-
sectomy in Colorectal Cancer.
Stage 1: 512
Not randomised: 419
Randomised: 93 Control: 47 Dead <5 years: 60
Alive >5 years: 23
Alive <5 years: 10
Metastasectomy: 46
Figure 2 Sankey flow diagram of trial outcomes. y, years.
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imbalances in the numbers of metastases between the
arms, which favoured the interventional arm [23,24].
The number of metastases is a powerful prognostic fact
with a hazard ratio for multiple vs solitary CRC lung
metastases of 2.04, and so it would have been better to
ensure balance in this factor [25]. In SABR-COMET,
there was an additional imbalance in cancer types, also
favouring the interventional arm. But it is the very simi-
lar and better-than-expected survival in the control arms
of all three trials that is important to note.
So where did the assumption of very poor survival in
untreated patients come from? The NICE source [5–7]
can be traced back to a 1994 paper confined to a retro-
spective analysis of liver resection [26]. Patients deemed
inoperable had poor survival but they bear no resem-
blance to candidates for lung metastasectomy. Then, in
a systematic review of CRC lung metastasectomy in
2013, the assumption was moderated to ‘5-year survival
rates worse than 5%’ [25]. Cited in support is a 1989
publication comparing five different methods of deliver-
ing fluorouracil to CRC patients who had characteristics
far worse than candidates for lung metastasectomy [27].
The few papers that address the question of survival
rates without metastasectomy use the <5% assumption,
referring to the systematic review or other secondary or
unsubstantiated sources. The Society of Thoracic Sur-
geons (STS) Work Force of Evidence Based Surgery
subjected pulmonary metastasectomy to an STS expert
consensus development process. Their publication, in
2019, cites 167 papers and they comment that: ‘meta-
static disease survival is assumed to be zero, a con-
tention not supported by the literature’ [28]. The
Table 4 Additional treatments.
(a) Numbers of patients and cycles of chemotherapy
Group N Treated Cycles Median Total cycles
Control 47 23 (49%) 1–6 3 68
Metastasectomy 46 19 (41%) 2–7 3 60
(b) Timing from randomisation in months
Group N < 6* 6–12 Earliest Median IQR
Control 47 9 3 0.4 11.6 2.3–16.4
Metastasectomy 46 6 7 1.0 7.8 5.4–14.1
(c) Radiotherapy and IGTA in months
Radiotherapy N < 6 6–12 > 12 Total
Control 47 0 1 3 4
Metastasectomy 46 0 1 4 5
IGTA N < 6 6–9 9–12 > 12 Total
Control 47 0 1 1 1 3
Metastasectomy 46 0 1 1 0 2
*Any differences may in part reflect considerations of fitness for chemotherapy in the post-operative period.
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current NICE guideline states that lung metastasectomy
should be ‘considered’ but provides no good evidence
of effectiveness [29].
If control 5-year survival was indeed 5%, an RCT in
40 patients could have shown the large difference
believed to be gained by lung metastasectomy. If sur-
vival in the metastasectomy group was expected to be
40%, then the power to detect an effect in a trial with
20 patients in each arm would be 83%. Large effects,
where they exist, can be shown with small trials. The
feasibility of such a trial was considered at the Mayo
Clinic in 1992, with a similar estimate of the required
power, but no trial was carried out [30,31].
High on the list of research priorities of the
ACPGBI is the question ‘Can early markers of meta-
static disease be developed?’ [14]. There is ample evi-
dence that earlier detection of metastases does not
lengthen survival. A systematic review found 16 RCTs
comparing standard with more intensive surveillance in
patients treated for early CRC. Meta-analysis of 11
RCTs with adequate data found that more intensive
monitoring advanced detection of metastases by a med-
ian of 10 months. As a result, there were more metasta-
sectomy operations, but no resulting survival benefit
[32]. In fact, in the largest three RCTs included (33–
35), there was an adverse effect on survival despite
higher detection. These findings were confirmed by a
separately conducted Cochrane review and meta-analysis
[36]. The British Journal of Surgery’s editor regarded
the conclusion as ‘bleak nihilism’ and wrote ‘it is coun-
terintuitive that earlier identification of metastatic dis-
ease does not improve survival’ [32], an opinion
counter to evidence. Uncertainty about the yield from
metastasectomy was expressed by the authors of a
meta-analysis of CRC survival gains who noted ‘that
while indeed more metastasectomies are being per-
formed, they have been made possible by better thera-
pies and that this benefit should be ascribed to the
therapies’. This raises the possibility of reverse causation
[10] – longer survival providing opportunities for more
treatments rather than additional treatments necessarily
resulting in longer survival.
In view of all these uncertainties and the results of
PulMiCC, the widespread belief in the value of metasta-
sectomy needs to be challenged. Large, definitive ran-
domized trials, investigating the possible benefits of the
practice of pulmonary metastasectomy for any tumour
type, are clearly needed and should be based on the
realistic survival figures that three small randomized tri-
als have provided. Meanwhile, the results of PulMiCC
should inform clinical practice, and patients who are
offered metastasectomy (whether surgical or by abla-
tion) should be clearly told about the uncertain benefits
and possible risks.
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